The Company is led by a lean management team with over 70 years of combined industry experience in the field of drug and antibody related discovery, research and development & commercialization.
Masanobu Tsukagoshi, Chief Executive Officer
The strategic and business activities of the company are led by Masanobu “Mas” Tsukagoshi. Mr. Tsukagoshi, also known as Mas, is a Venture Partner at incTANK Ventures. His areas of focus are in the materials and computational sciences sectors. Mr. Tsukagoshi has delivered lectures on entrepreneurship and intellectual property strategies at the University of Tokyo, Kyoto University, and Nagoya University. He has over 13 years of experience in new issue syndication and multi-currency illiquid asset management. Mas earned a C.B.A. from Konan University and an MBA in International Finance from the University of Pittsburgh. Mas is a recipient of Distinguished Service Award 2012 from Katz School of the University of Pittsburgh, and most recently, Intellectual Property Achivement Award 2020 from Japan Patent Office/Ministry of Economy, Trade and Industry of Japan.
Masayuki Tsuchiya, PHD, Chief Technology Officer
Dr. Tsuchiya joins Savid Therapeutics to lead the clinical development program for Savid’s lead compounds and to help guide Savid business and partnership opportunities. Dr. Tsuchiya brings over 30 years of drug research and development as a leader at Chugai Pharmaceuticals. Dr. Tsuchiya led the research teams as Director of Research and later initiated the antibody drug development programs for Chugai as Director of Antibody Research. After Chugai Pharmaceuticals merged with Roche Pharmaceuticals, Dr Tsuchiya expanded his role at the company to become the Director of Life Cycle Management for all Chugai Pharmaceutical drugs. Dr. Tsuchiya is a well-known industry expert that brings a lifetime of research, development and business experience to the Savid team.
Michael Chansler, Vice President Business Development
Michael’s career has been focused on business development, strategic relationships management and commercialization for drug development, clinical diagnostics, and life sciences research products companies in the US, Europe and Asia. Most recently as Director Business Development of PATH he identified a pipeline of funding and collaboration opportunities for the PATH drug development program’s priority areas, helped to sharpen business development strategy, and helped connect projects with traditional and new sources of funding. As the Senior Director of Business Development and Commercialization at Battelle Memorial Institute in Columbus, Ohio, Michael built partnerships, led proposal development, and managed complex relationships for international projects. Michael brings over 25 years of experience in business development, partnership management, and commercialization for a variety of contract research organizations and product research and development companies. Michael earned his BS in Biological Sciences from the University of Maryland. He serves on the board of two international charities, and volunteers actively in developing countries.
Tatsuhiko Kodama, MD, Ph.D, Professor Emeritus, the University of Tokyo,
The Savid technology was invented by and the technical team is guided by Dr. Kodama who has led the Laboratory for Systems Biology and Medicine (LSBM) at the University of Tokyo. His research teams identify target proteins for drug development focusing on cancer and metabolic disorders. Professor Kodama was instrumental in the founding of Savid for the development and commercialization of his inventions.
The Board of Directors is composed of individuals with strong pharmaceutical industry ties, venture capital experience and strong entrepreneurial thinking.